References of "Ries, G"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPrognostic Factors in Urothelial Renal Pelvis and Ureter Tumours: a Multicentre Rare Cancer Network Study
Ozsahin, M; Zouhair, A; Villa, S et al

in European Journal of Cancer & Clinical Oncology (1999), 35/5

To assess the prognostic factors in patients with transitional-cell carcinoma of the renal pelvis and/or ureter, a series of 138 patients with transitional-cell carcinoma of the renal pelvis and/or ureter ... [more ▼]

To assess the prognostic factors in patients with transitional-cell carcinoma of the renal pelvis and/or ureter, a series of 138 patients with transitional-cell carcinoma of the renal pelvis and/or ureter was collected in a retrospective multicentre study. 12 patients with distant metastases were excluded from the statistical evaluation. All but 3 patients underwent radical surgery: nephroureterectomy (n=71), nephroureterectomy and lymphadenectomy (n=20), nephroureterectomy and partial bladder resection or transurethral resection (n=20), nephrectomy (n=10), and ureterectomy (n=5). Sixty-one per cent (n=77) of the tumours were located in the renal pelvis, and 21% (n=27) in the ureter (both in 22 [17%]). Following surgery, residual tumour was still present in 33 patients (16 microscopic and 17 macroscopic). Postoperative radiotherapy was given to 45 (36%) patients. The median follow-up period was 39 months. In a median period of 9 months, 66% of the patients relapsed (34 local, 7 locoregional, 16 regional, and 24 distant). The 5- and 10-year survival were 29% and 19%, respectively, in all patients. In univariate analyses, statistically significant factors influencing the outcome were Karnofsky index, pT-classification, pN-classification, tumour localisation, grade, and residual tumour after surgery. Multivariate analysis revealed that independent prognostic factors influencing outcome were pT-classification, the existence of residual tumour, and tumour localisation. In patients with urothelial renal pelvis and/or ureter tumours, a radical surgical attitude is mandatory; and the presence of tumour in the ureter is associated with a poorer prognosis. [less ▲]

Detailed reference viewed: 36 (6 ULg)
Full Text
Peer Reviewed
See detailPrognostic factors in urothelial renal pelvis and ureter tumors: A multicenter Rare Cancer Network study
Ozsahin, Mahmut; Zouhair, Abderrahim; Villà, S. et al

in International Journal of Radiation, Oncology, Biology, Physics (1997), 3(2(supp)), 290

Detailed reference viewed: 5 (2 ULg)
Full Text
Peer Reviewed
See detailT92-0045: Interlaboratory quality control on Tpot measurements
Coucke, Philippe ULg; Beer, K.; Bernier, J. et al

in International Journal of Radiation, Oncology, Biology, Physics (1996), 36(1(supp1)), 384

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailPrognosis of human chorionic gonadotropin-producing seminoma treated by postoperative radiotherapy
Mirimanoff, R-O; Sinzig, M; Krüger, M et al

in International Journal of Radiation, Oncology, Biology, Physics (1993), 27(1), 17-24

To clarify the controversy about the management and prognosis of human chorionic gonadotropin-producing seminoma, the records of 132 patients with abnormal human chorionic gonadotropin values treated with ... [more ▼]

To clarify the controversy about the management and prognosis of human chorionic gonadotropin-producing seminoma, the records of 132 patients with abnormal human chorionic gonadotropin values treated with radiotherapy were analyzed. METHODS AND MATERIALS: The records of 1169 patients with pure seminoma treated in 10 institutions were screened for serum or urinary human chorionic gonadotropin. One hundred and thirty two patients with elevated human chorionic gonadotropin were found: 96 Stage I, 20 IIA, 7 IIB, 8 III and 1 IV. Median age was 34 y., mean follow-up was 5.0 years [range 1-12 y]. All received infradiaphragmatic radiotherapy (median dose 30 Gy), 25 (2 Stage I, 11 IIA, 5 IIB and 7 III) supradiaphragmatic radiotherapy (median dose: 28.5 Gy) and 10 had also initial chemotherapy (3 Stage IIB 6 III and 1 IV). Patients were allocated to three groups according to human chorionic gonadotropin values: (a) moderate elevation: up to 10 times (104 pts), (b) high elevation: 10 to 100 times (20 pts), (c) very high elevation: over 100 times the upper limit of normal value (8 pts). RESULTS: The proportion of Stage I, II and III was 76%, 19%, 5% in the ME group versus 50%, 35%, 15% in the high elevation group (p < 0.05). In the very high elevation group there were 7 Stage I and 1 Stage IV. Of 132 patients, six died (three dead of disease, two suicides, one acquired immunodeficiency syndrome). The 5 years overall survival probability was 94%. There were seven recurrences (initial stage: 1 Stage I, 2 IIB, 3 III and 1 IV). Of these, there were one in-field recurrence, 3 out of field and 3 in both sites. In 5 of 7, the human chorionic gonadotrophin level was again elevated at recurrence. The 5 years recurrence-free-survival probability was 94% (98% for Stage I, 100% for Stage IIA and 65% for Stage IIB and III [p < 0.001 between I and IIB + III, p < 0.05 between IIA and IIB + III]). Four of the 7 recurrences were salvaged by chimiotherapy +/- radiotherapy. In the high elevation and very high elevation groups, the 5 years recurrence-free-survival was 88%, vs. 96% for the moderate elevation group (p = 0.10). CONCLUSION: Based on this series of patients, human chorionic gonadotropin production is not an unfavorable prognostic factor in pure seminoma. Even in the subgroups with high or very high human chorionic gonadotropin levels (who had a higher proportion of advanced stages), the prognosis remained excellent. In Stage I and IIA seminoma with abnormal human chorionic gonadotropin levels, recurrence rate after post-operative radiotherapy alone is extremely low. [less ▲]

Detailed reference viewed: 19 (0 ULg)